Cationic lipid-mediated gene transfer is a safe and effective means of delivering potent immunomodulatory cytokines directly into tumors. This approach avoids undesirable side effects, including systemic toxicities. To investigate key factors affecting intratumoral (i.t.) gene transfer, cationic lipid-DNA complexes were injected into subcutaneous human melanoma tumors in severe combined immunodeficient mice. Animals received i.t. injections of VR1103, a DNA plasmid encoding the gene for human interleukin-2 (IL-2), either alone or complexed with the cationic lipid N-(1-(2,3-dimyristyloxypropyl)-N,N-dimethyl-(2-hydroxyethyl) ammonium bromide/dioleoyl phosphatidylethanolamine (DMRIE/DOPE). Tumors were subcultured and supernatants were tested for IL-2 secretion by enzyme-linked immunosorbent assay. IL-2 secretion was consistently higher when lipid:DNA (L:D) complexes were formulated at high L:D ratios (wt/wt), and IL-2 transgene expression increased in a DNA dose-dependent manner. A comparison of naked plasmid and lipid-complexed DNA revealed that lipid complexes were more effective for i.t. gene transfer. Using an enhanced green fluorescent protein reporter plasmid and flow cytometry, i.t. transfection efficiency was 1.74% (Ϯ 1.08%). Tumor injection technique, including injection volume and location, had a limited impact on i.t. gene transfer. These results indicate that the formulation and dosage of cationic L:D complexes, but not injection technique, play a key role in determining the level of i.t. transgene expression. Cancer Gene Therapy (2000) 7, 853-860
T he need for an efficient, nonviral gene transfer system for cancer immunotherapy stems from the persistent problems associated with viral vectors. 1 Problems associated with immunogenicity, the development of replication-competent viruses, and potential oncogenic activity have encouraged the development of safe and effective nonviral gene transfer systems. [2] [3] [4] [5] Cationic lipids are widely used for in vivo gene transfer because of their ease of use and high in vitro transfection efficiency. 1, 6, 7 Intratumoral (i.t.) gene transfer is an active area of investigation, as it targets gene delivery directly to tumor cells, while eliminating the time and cost associated with ex vivo gene therapy protocols. 8 In addition, many groups have demonstrated preclinical efficacy using i.t. cationic lipid-mediated gene transfer of cytokines, 9, 10 alloantigens, 11 and prodrug-converting enzymes. 12 Still, variability of i.t. transfection and low transfection efficiency are problems associated with lipid-mediated gene transfer in vivo. 13 Cationic lipids were originally developed as a method of delivering DNA into monolayer cultures under strictly controlled conditions. 14 In this setting, lipid complexes are a highly efficient means of introducing DNA into tumor cells. However, transfection efficiency after i.t. injection of lipid:DNA (L:D) complexes is often low (estimated at between 0.05% and 1.0%). 10, 15 It is generally believed that improvements in cationic lipid gene transfer efficiency can be achieved. Therefore, novel cationic lipid reagents, employing unique chemistries, are being developed; in addition, research is underway to understand the structure-function relationships of this emerging technology. 16, 17 The in vitro transfection activity of a particular cationic lipid seldom predicts its in vivo activity, 6, 18 and there are few standards regarding the most efficient means of using lipid complexes for i.t. transfection. 19 Some investigators have reported inhibition of i.t. plasmid transfection due to cationic lipids, 20 and have achieved better results with naked DNA instead. Thus, studies are needed to clarify the factors that influence in vivo cationic lipid gene transfer in tumor nodules. In this paper, we report results from our studies on i.t. gene transfer after injection of L:D complexes into human melanoma xenografts growing in severe combined immunodeficient (SCID) mice.
MATERIALS AND METHODS

Reagents and cell lines
Opti-MEM, RPMI 1640, Hanks' balanced salt solution (HBSS), and trypsin were obtained from Life Technologies (Gaithersburg, Md). Fetal bovine sera (FBS) and penicillin/ streptomycin were purchased from Gemini Bio-Products (Calabasas, Calif).
The plasmids used for transfection were VR1103, 21, 22 which contains the cDNA for human interleukin-2 (hIL-2), and pK4, which is an enhanced green fluorescent protein (EGFP)-containing reporter plasmid derived from pEGFP-1 (Clontech, Palo Alto, Calif). Both expression cassettes are driven by the cytomegalovirus immediate/early promoter. DMRIE/DOPE is a 1:1 molar mix of N- (1-(2,3-dimyristyloxypropyl) -N,N-dimethyl-(2-hydroxyethyl) ammonium bromide (DMRIE) and dioleoyl phosphatidylethanolamine (DOPE). 23 VR1103 and DMRIE/ DOPE were kind gifts of Vical, Inc. (San Diego, Calif).
UM449 cells were maintained in RPMI 1640 supplemented with 10% FBS and 100 g/mL streptomycin (complete media). UM449 is a cell line derived from a human melanoma and was generously provided by Dr. A. Chang (University of Michigan, Ann Arbor, Mich).
Animals and tumors
Six-to ten-week-old SCID (C.B-17 scid/scid) mice were purchased from the University of Arizona Animal Care Facility and housed in microisolator cages. UM449 cells were trypsinized and collected during log growth, washed, and resuspended in HBSS. Bilateral, subcutaneous (s.c.) tumors (four tumors per animal) were established by injecting 1 ϫ 10 6 UM449 cells into the flanks and backs of SCID mice.
In vitro transfection
UM449 cells were seeded at 70% confluence in 6-well plates. DMRIE/DOPE and plasmid DNA were diluted separately in serum-free Opti-MEM media, mixed together, and incubated at room temperature for 15 minutes. L:D complexes, at the indicated ratios, were transferred to individual wells followed by an equal volume of Opti-MEM containing 20% FBS and penicillin/streptomycin. Cells were incubated for 24 hours and supplemented with fresh Opti-MEM containing 10% FBS (10% Opti-MEM) before analysis of transgene expression.
hIL-2-specific enzyme-linked immunosorbent assay (ELISA)
Immulon 2 microtiter plates (Dynatech Laboratories, Chantilly, Va) were coated with 1 g/mL MAB202, an anti-hIL-2 antibody (R&D Systems, Minneapolis, Minn), that had been diluted in phosphate-buffered saline (PBS) for Ͼ12 hours at 4°C. Cell culture supernatants and hIL-2 standards (generously provided by Cetus, Emeryville, Calif) in 10% Opti-MEM were added to coated 96-well plates and incubated for 2 hours at room temperature with constant shaking. Horseradish peroxidase-conjugated anti-hIL-2 (Medgenix Diagnostics S.A., Fleurus, Belgium) diluted in 0.1% bovine serum albumin in PBS was added to each well and incubated for 2 hours at room temperature with constant shaking. Bound horseradish peroxidase was detected by measuring the absorbance of 3,3Ј,5,5Ј-tetramethyl-benzidine substrate conversion at 450 nm.
Intracellular IL-2 flow cytometry
Transfected cells were harvested from 6-well culture dishes with 1 mM ethylenediaminetetraacetic acid in 1ϫ PBS and fixed in 4% paraformaldehyde/PBS for 15 minutes at room temperature. Cells were permeabilized with 0.2% Triton X-100 for 5 minutes, stained with a primary anti-hIL-2 (MAB202) antibody diluted to 5 g/mL in 0.1% bovine serum albumin/PBS, washed, and stained with a 1/100 dilution of goat anti-mouse R-phycoerythrin fluorescent secondary antibody (Boehringer Mannheim, Mannheim, Germany). Cells were washed and postfixed with 2% formaldehyde/PBS in preparation for flow analysis. Analysis of at least 10,000 cells was performed on a Becton Dickinson FACScan (Becton Dickinson, Mountain View, Calif).
I.t. injection of UM449 tumors in SCID mice
UM449 tumors were implanted s.c. in SCID mice and grown to ϳ0.5-1 cm in diameter. Four tumors were established in each animal. L:D complexes were prepared by first diluting DMRIE/ DOPE into sterile saline followed by slow addition of VR1103. Naked DNA was diluted in sterile saline. Animals were anesthetized using a cocktail of ketamine HCl (Mallinckrodt, Mundelein, Ill), xylazine, and acepromazine maleate (Butler Company, Columbus, Ohio). Unless otherwise indicated, tumors were injected once with 100 or 50 L of plasmid prepared at the indicated L:D ratios and were removed at 24 -48 hours postinjection. Each tumor was weighed and subsequently disaggregated in 1 g/mL collagenase A (Boehringer Mannheim) and 0.02% deoxyribonuclease I (Sigma, St. Louis, Mo) for 4 hours at 37°C. Single-cell suspensions from each tumor were counted using trypan blue, and 5 ϫ 10 5 viable cells were subcultured in RPMI 1640 plus 10% FBS plus penicillin/ streptomycin for 24 hours. Supernatants were collected, and IL-2 expression was quantitated using a hIL-2-specific ELISA. A viable cell count from each individual well was used to normalize IL-2 expression.
RESULTS
In vitro transfection with L:D complexes
Optimal L:D ratios for in vitro transfection of UM449 cells were determined using VR1103, a plasmid containing the hIL-2 cDNA. A total of 10 g of VR1103 was combined with DMRIE/DOPE at five different ratios; UM449 cells, cultured in 6-well plates, were transfected and analyzed at 48 hours posttransfection. Increasing the ratio of L:D (wt/wt) from 1:5 (Ϯ charge ratio of 0.05:1) to 3.8:1 (Ϯ charge ratio of 0.9:1) resulted in a 2-fold increase in IL-2 secretion (from 12,000 international units (IU)/mL at an L:D ratio of 1:5 to 25,000 IU/mL at an L:D ratio of 3.8:1) (Fig 1) . Fluorescent immunocytochemical staining of intracellular IL-2 showed that the percentage of transfected cells increased from 30% to 75% as the L:D ratio increased (Fig 1) . Therefore, in vitro transgene expression can be increased by increasing the L:D ratio for a given DNA dose. 6 cells/24 hours, a 6.5-fold increase (P Ͻ .0005). At the highest ratio of 5:1, we observed an unexpected reduction in transgene expression. We believe that this result is due to L:D complex precipitation, which commonly occurs at high lipid and DNA concentrations. Handling and injection of precipitated lipid complexes is difficult and unreliable.
Effect of L:D ratio on in vivo transfection
Dose escalation studies
To determine the effect of plasmid DNA dose on transgene expression, we performed a DNA dose escalation study, using doses of 1, 5, and 25 g of VR1103, at our most effective L:D ratio of 2.5:1. Formulated in 50 L of saline, L:D complexes prepared with DNA doses of Ͼ25 g were unstable and were therefore not tested. IL-2 transgene expression increased in a linear, but not proportional, fashion with DNA dose (Fig 3) .
Comparison of naked and lipid-complexed plasmid DNA in vivo
We also investigated the capacity of cationic lipids to enhance i.t. gene transfer over naked DNA alone. S.c. UM449 tumors grown in SCID mice were injected with VR1103 diluted in sterile saline or complexed with DMRIE/DOPE at an L:D ratio of 2.5:1. These studies were performed at DNA doses of 10 and 40 g VR1103/ tumor. At 40 g/tumor, the addition of DMRIE/DOPE substantially improved IL-2 transgene expression when compared with naked DNA alone, producing a 6.7-fold (P Ͻ .0001) increase in IL-2 secretion (Fig 4) . A 6.1-fold (P Ͻ .05) increase in IL-2 secretion was recorded with the low 10-g DNA dose when DMRIE/DOPE was added (data not shown).
Duration of transgene expression
To determine IL-2 expression persistence in vivo, tumors were removed at different intervals after i.t. injection of L:D complexes. IL-2 expression was detected in cultures when tumors were removed at 2 and 5 days, but not 8 days after DNA injection, and no IL-2 was detected in tumors injected with DMRIE/DOPE alone (Fig 5a) . We were also interested in determining whether the levels of IL-2 secreted by injected tumors were sufficient to produce systemic IL-2 transgene expression. Animals bearing two VR1103-injected tumors (total DNA ϭ 40 g; L:D ratio of 2.5:1) were sacrificed at 2, 5, and 8 days postinjection and tested for serum IL-2. IL-2 transgene expression was found at the earliest timepoint, but fell to undetectable levels by day 5 (Fig 5b) . These results mirror the profile of IL-2 secretion recorded from individual tumors (Fig 5a) .
Determining the transfection efficiency of cationic lipid-mediated gene transfer in vivo is technically challenging. Recently, reporter plasmids containing green fluorescent protein (GFP) cDNA have become available. This transgene is readily detected in live cells by direct microscopy or flow cytometry, eliminating the need for secondary enzymatic reactions to quantitate gene expression. We tested the i.t. transfection efficiency of our L:D complexes by injecting 50 g of DMRIE/ DOPE complexed with 20 g of pK4, an EGFP reporter plasmid, into s.c. UM449 tumors. After tumor disaggregation, cells were subcultured for 24 hours and GFP expression was measured by flow cytometry. In two separate experiments, i.t. transfection efficiency was found to be 1.74% Ϯ 1.08 (range ϭ 0.70 -3.87%) ( Table  1 ). The process of evaluating lipids for i.t. gene transfer activity is resource-and time-consuming; this technique provides a reliable and cost-efficient means of conducting this task. The physical distribution of lipid complexes within a tumor may also play a role in i.t. transfection. For example, multiple injections throughout the tumor might distribute plasmid more efficiently than a single bolus injection.
Tumor injection methods and i.t. transgene expression
To test this hypothesis, L:D complexes containing 50 g of DMRIE/DOPE and 20 g of VR1103 (L:D ratio of 2.5:1 (wt/wt)) in 50 L were either injected into the center of the tumor ("central bolus") or injected by fractions throughout the tumor ("multiple injection") from a single injection site. The central bolus injection was numerically superior to the multiple injection technique; however, neither method proved to be statistically superior (Fig 7a) . Likewise, avoiding the necrotic and hypoxic areas of the tumor during injection may increase DNA delivery to metabolically active tumor tissue and thereby increase transfection rates. We injected L:D complexes at 1-2 mm within the tumor and compared this technique with injections delivered to central areas of the tumor. We were unable to demonstrate any benefit of injection at the periphery of s.c. tumors, as injection at the periphery of the tumor versus the center produced 319.2 vs. 263.0 IU of IL-2/10 6 cells/24 hours, respectively (Fig 7b) .
DISCUSSION
The goal of these studies was to better understand the factors that influence cationic lipid-mediated gene transfer in solid tumors and, in particular, to determine the impact of L:D formulation and injection methodologies on i.t. transfection. Cationic lipids are a highly effective means of delivering plasmid DNA into cells in vitro; however, little transgene expression is seen when naked plasmid DNA is used to transfect cultured cells. 24 Interestingly, numerous reports have demonstrated that naked plasmid DNA can be as effective as lipid-complexed DNA for transfecting some tumors in vivo. 13, 25, 26 Our results with naked plasmid DNA and lipid-complexed DNA show that DMRIE/DOPE significantly improves the i.t. transfection of s.c. UM449 tumors (Fig 4) . Why cationic lipids provide a benefit for gene transfer in some tumor models while inhibiting transfection in others is still unknown. It is almost certain that the choice of cationic lipid and formulations used can dramatically affect the *UM449 tumors were injected with 20 g of pK4 (GFP-encoding plasmid) admixed with 50 g of DMRIE/DOPE. At 24 hours postinjection, tumors were removed, enzymatically dissaggregated, and subcultured in 6-well plates. After overnight culture, cells were collected using 1 mM ethylenediaminetetraacetic acid in HBSS and were analyzed directly on a Becton Dickenson FACScan.
outcome of i.t. gene transfer. The first consideration for successful i.t. gene transfer is choosing an active cationic lipid suitable for the tumor. It appears that many cationic lipids exhibit tissue tropism for normal tissues (e.g., lung epithelium). 6 It is reasonable to assume that this tropism extends to tumors derived from different histologic sources as well. A given cationic lipid may exhibit differential activity in different tumor types depending upon many factors, including fluid content, vascularity, and extracellular matrix composition. Egilmez et al 13 showed that four of five cationic lipids, including DMRIE/DOPE, were no better than plasmid DNA at transfecting a s.c. squamous cell carcinoma tumor; however, DMRIE/DOPE produced significant benefits in gene transfer in our human melanoma xenograft (Fig 4) . Similarly, Lipofectamine has been shown to dramatically reduce plasmid transfection in a murine melanoma xenograft (BL6: derived from B16-F10) after i.t. injection, 25 yet produces surprisingly high transfection efficiencies in a C6 rat glioma model. 27 These seemingly contradictory results illustrate that cationic lipids behave differently depending upon the tissue type investigated.
A second consideration for successful i.t. gene transfer with cationic lipids pertains to the choice of L:D ratio used. L:D ratios have been shown to affect systemic, 28, 29 pulmonary, 30, 31 and i.t. 13, 25 gene transfer with cationic lipids. Using our i.t. gene transfer model, we tested the potency of two separate DMRIE/DOPE:VR1103 formulations at ratios of 1:2.5 and 2.5:1 (wt/wt). L:D complexes prepared at the 2.5:1 ratio produced six times more IL-2 transgene product compared with complexes prepared at 1:2.5 (Fig 2) . These studies emphasize the importance of optimizing L:D ratios for i.t. gene transfer. Optimized L:D complexes may produce particles that (a) are more resistant to nuclease digestion, 32 (b) contain highly potent L:D complex conformations, 17 or (c) are more efficiently retained within the tumor (see below).
An unexpected benefit of complexing plasmid DNA with cationic lipids is improved DNA retention within the tumor. Using a Walker 256 carcinoma in Wistar rats, Nomura et al 26 reported that 50% of naked DNA is cleared from injected tumors within 2 hours, whereas 93.7% of lipid-complexed DNA remains within the tumor during the same time period. In addition to loss via lymphatic or venous routes, we found that plasmid loss occurs from the injection site as well (our unpublished observation). We have observed less DNA leakage from the tumor injection site when plasmid DNA was complexed with cationic lipids, and these tumors expressed 4.06-fold more IL-2 transgene product than those injected with naked DNA alone. Thus, cationic lipids may improve i.t. transgene expression by reducing plasmid DNA loss from the tumor injection site.
Cationic lipid-mediated transfection occurs most effectively in actively proliferating cells, 33, 34 and predictably, little i.t. transfection occurs when lipid complexes are injected into necrotic tissue. 26 With these results in mind, we have investigated three ways to maximize the . a: Lipid complexes were either bolus injected into the center of the tumor (central bolus injection) or injected as fractions throughout the tumor from one injection site (multiple injection sites); n ϭ 11 and 11 tumors/group. Two-tailed Student's t test: P ϭ not significant. b: Tumors were bolus injected with the needle bevel 1-2 mm into the tumor ("peripheral bolus injection") or with the bevel in the center of the tumor (central bolus injection). Tumors were removed, disaggregated, and subcultured in 12-well plates. Secreted IL-2 was measured with a hIL-2-specific ELISA. (n ϭ 9 and 7 tumors/group). Two-tailed Student's t test: P ϭ not significant. distribution of lipid complexes throughout the tumor while avoiding potentially "unproductive" tissues. First, increasing injection volumes may increase plasmid distribution within the tumor. Our studies indicate that an intermediate injection volume of 30 L, equal to 24% of the average tumor volume (125 mg), resulted in the greatest transgene expression compared with 10-or 100-L volumes (Fig 6) . These results, although not statistically significant, were reproducible for L:D complexes and naked DNA injections alike (data not shown). Intermediate volumes may allow sufficient plasmid distribution within the tumor while minimizing loss due to leakage. Second, efforts to avoid injecting into the center of a tumor, which is often composed of hypoxic and necrotic tissue, may improve plasmid delivery to proliferating tumor cells. Injection of lipid complexes at the periphery of the tumor does produce a modest (21%) but reproducible improvement in transgene expression compared with injection into the center of the tumor (Fig 7b) . Finally, i.t. distribution of L:D complexes may be improved by injecting into numerous sites within a tumor. Injection of naked DNA at multiple sites in a tumor failed to increase i.t. transgene expression. 25 However, multiple injections have been reported to increase gene expression when Lipofectamine:DNA complexes were injected into s.c. rat glioma tumors. 27 In our studies, we tested a variation of this technique by distributing DMRIE/VR1103 complexes throughout the tumor from a single injection site using a Z-track injection method (insertion of the needle bevel to the distal portion of the tumor and injecting fractions of the dose while retracting the needle in a Z-track pattern). This approach did not improve transgene expression and was less successful than bolus injection into the center of the tumor (Fig 7a) . Needle movement within the tumor may cause excessive bleeding and tissue damage, interfering with the transfection process. Individually, tumor injection technique and location did not significantly alter the outcome of i.t. transfections in our studies. However, when taken together, these modest improvements in gene transfer may lead to increased transgene expression and improved biologic effects.
In this report, we define key factors controlling i.t. transfection efficiency with L:D complexes. Plasmid DNA injection dose, the presence or absence of cationic lipid, and L:D formulation are key factors contributing to the outcome of i.t. transfections. Other factors, including injection volume, injection location, and DNA loss, may contribute to this process, but only in a minor way.
